Last update March 26, 2020

Darunavir

Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Antivírico inhibidor de la proteasa del VIH. Utilizado, solo o asociado a Cobicistat o Ritonavir o Elvitegravir, en el tratamento del VIH/SiDA (Navarro 2016.
Se ha empleado de modo experimental en el tratamiento de la infección por coronavirus COVID-19 (SEFH 2020).
Administración oral en una o dos dosis diarias.

A fecha de última actualización no encontramos datos publicados sobre su excreción en leche materna.

Sus datos farmacocinéticos (muy amplio volumen de distribución, peso molecular moderadamente elevado y muy alto porcentaje de fijación a proteínas) hacen poco probable el paso a leche materna de cantidades significativas.
De otros inhibidores de la proteasa semejantes, como el Lopinavir y el Ritonavir, se sabe que se excretan en cantidad ínfima en leche materna (Oumar 2018, Corbett 2014, Shapiro 2013, Palombi 2012).

Los efectos secundarios posibles son raros y, en general, de gravedad leve-moderada: diarrea, nauseas, exantema... (Navarro 2016).

Según la política adoptada en cada país, la lactancia materna en madres con VIH / SIDA está o no aconsejada. Con el tratamiento antirretroviral de gran actividad (TARGA) la carga viral para VIH se puede reducir a cero, reduciendo el riesgo de transmisión de VIH a través de la lactancia materna a niveles semejantes a los de la alimentación con fórmula artificial.


See below the information of these related products:

  • Cobicistat (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Lopinavir ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Maternal Aids ( Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.)
  • Maternal Coronavirus 2019-nCoV infection (COVID-19) ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Ritonavir ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Alternatives

  • Lopinavir ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Ritonavir ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Darunavir is also known as


Darunavir in other languages or writings:

  • (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl N-[(1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl]carbamate (Chemical name)
  • C27 H37 N3 O7 S (Molecular formula)
  • J05AE10 (ATC Code/s)
  • TMC-114; UIC-94017 (Experimental code/s)
  • Дарунавир (Cyrillic)
  • دارونافير (Arabic)
  • ダルナビル (Japanese)

Group

Darunavir belongs to this group or family:

Tradenames

Main tradenames from several countries containing Darunavir in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 37; ( + ritonavir = 82 ) %
Molecular weight 548 daltons
Protein Binding 95 %
VD 1,2 - 3,14 l/Kg
pKa 11,4 -
Tmax 2,5 - 4 hours
T1/2 15 hours

References

  1. SEFH - Sociedad Española de Farmacia Hospitalaria. Procedimientos de farmacia hospitalaria para la gestión del tratamiento con antivirales en la enfermedad por el nuevo coronavirus sars-cov-2 (COVID-19). Recomendaciones de la Sociedad Española de Farmacia Hospitalaria. 2020 Full text (in our servers)
  2. Oumar AA, Bagayoko-Maiga K, Bahachimi A, Maiga M, Cere MC, Diarra Z, Chatelut E, Sylla M, Murphy RL, Dao S, Gandia P. Efavirenz and Lopinavir Levels in HIV-Infected Women and Their Nursing Infants, in Mali. J Pharmacol Exp Ther. 2018 Sep;366(3):479-484. Abstract
  3. AEMPS-Reddy. Darunavir. Ficha técnica. 2018 Full text (in our servers)
  4. Navarro J, Curran A. Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS. HIV AIDS (Auckl). 2016 Oct 31;8:175-182. eCollection 2016. Review. Abstract
  5. Corbett AH, Kayira D, White NR, Davis NL, Kourtis AP, Chasela C, Martinson F, Phiri G, Musisi B, Kamwendo D, Hudgens MG, Hosseinipour MC, Nelson JA, Ellington SR, Jamieson DJ, van der Horst C, Kashuba A; BAN Study Team.. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post-partum: results of the BAN Study. Antivir Ther. 2014;19(6):587-95. Abstract
  6. EMA - Jansen C. Darunavir-Cobicistat (Rezolsta). Ficha técnica. 2014 Full text (in our servers)
  7. Shapiro RL, Rossi S, Ogwu A, Moss M, Leidner J, Moffat C, Lockman S, Moyo S, Makhema J, Essex M, Capparelli E. Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. Antivir Ther. 2013;18(4):585-90. Abstract
  8. Palombi L, Pirillo MF, Andreotti M, Liotta G, Erba F, Sagno JB, Maulidi M, Ceffa S, Jere H, Marchei E, Pichini S, Galluzzo CM, Marazzi MC, Vella S, Giuliano M. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir Ther. 2012;17(8):1511-9. Abstract

Total visits

1,386

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM